Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer

Inavolisib in combination with palbociclib and fulvestrant is in clinical development for the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), PIK3CA-mutated locally advanced or metastatic breast cancer. Breast cancer occurs when abnormal cells in the breast begin to grow and divide in an uncontrolled way and eventually form a growth (tumour). The PIK3CA gene holds the instructions for making a protein called p110 alpha (p110α) responsible for cell growth and division, cell movements, and protein production. A mutation in the PIK3CA gene can disrupt this process.. Symptoms can sometimes include fatigue, hair loss, general pain, lump in breast, and nausea, People diagnosed with HR+ metastatic breast cancer often face the risk of disease progression and treatment side effects, creating a need for additional treatment options.